Literature DB >> 14607314

Pathological heterogeneity of clinically diagnosed corticobasal degeneration.

M Doran1, D G du Plessis, T P Enevoldson, N A Fletcher, E Ghadiali, A J Larner.   

Abstract

Two patients fulfilling suggested clinical diagnostic criteria for corticobasal degeneration (CBD) are presented, who were found at postmortem to have alternative pathological diagnoses not suspected during life, namely, Alzheimer's disease and Pick's disease, respectively. The nosological position of these cases is considered in light of a literature review of previous reports of clinically diagnosed corticobasal degeneration with atypical (not corticobasal degeneration) pathology. Since such phenocopies may be common, we suggest that all clinically diagnosed cases of corticobasal degeneration should initially be labelled as "corticobasal degeneration syndrome" (CBDS) to emphasize that this is a diagnosis based on clinical phenotype, with the term corticobasal degeneration being reserved for the specific neuropathological phenotype, which itself may have a variety of clinical presentations.

Entities:  

Mesh:

Year:  2003        PMID: 14607314     DOI: 10.1016/s0022-510x(03)00232-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

Review 1.  The corticobasal syndrome-Alzheimer's disease conundrum.

Authors:  Anhar Hassan; Jennifer L Whitwell; Keith A Josephs
Journal:  Expert Rev Neurother       Date:  2011-11       Impact factor: 4.618

2.  Corticobasal syndrome due to a thalamic tuberculoma and focal cortical atrophy.

Authors:  K R Mridula; S Alladi; D R Varma; J R Chaudhuri; Y Jyotsna; R Borgohain; S Kaul
Journal:  BMJ Case Rep       Date:  2009-02-02

3.  Corticobasal degeneration: clinical characteristics and multidisciplinary therapeutic approach in 26 patients.

Authors:  Hatem S Shehata; Nevin M Shalaby; Eman H Esmail; Ebtesam Fahmy
Journal:  Neurol Sci       Date:  2015-04-28       Impact factor: 3.307

4.  Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease.

Authors:  John M Ringman; Luis D Medina; Yaneth Rodriguez-Agudelo; Mireya Chavez; Po Lu; Jeffrey L Cummings
Journal:  Curr Alzheimer Res       Date:  2009-08       Impact factor: 3.498

5.  Imaging of corticobasal degeneration syndrome.

Authors:  Masamichi Koyama; Akira Yagishita; Yasuhiro Nakata; Masaharu Hayashi; Mitsuaki Bandoh; Toshio Mizutani
Journal:  Neuroradiology       Date:  2007-07-14       Impact factor: 2.804

6.  Corticobasal Syndrome in a Family with Early-Onset Alzheimer's Disease Linked to a Presenilin-1 Gene Mutation.

Authors:  Eloisa Navarro; Clara De Andrés; Carmen Guerrero; Santiago Giménez-Roldán
Journal:  Mov Disord Clin Pract       Date:  2015-07-25

7.  Dopamine Transporter SPECT Imaging in Corticobasal Syndrome.

Authors:  Roberto Cilia; Carlo Rossi; Daniela Frosini; Duccio Volterrani; Chiara Siri; Cristina Pagni; Riccardo Benti; Gianni Pezzoli; Ubaldo Bonuccelli; Angelo Antonini; Roberto Ceravolo
Journal:  PLoS One       Date:  2011-05-02       Impact factor: 3.240

8.  Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome.

Authors:  Nobutaka Sakae; Keith A Josephs; Irene Litvan; Melissa E Murray; Ranjan Duara; Ryan J Uitti; Zbigniew K Wszolek; Jay van Gerpen; Neil R Graff-Radford; Dennis W Dickson
Journal:  Alzheimers Dement       Date:  2019-08-06       Impact factor: 16.655

Review 9.  Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene.

Authors:  A J Larner; M Doran
Journal:  J Neurol       Date:  2005-11-04       Impact factor: 6.682

10.  Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography.

Authors:  Sharon J Sha; Pia M Ghosh; Suzee E Lee; Chiara Corbetta-Rastelli; Willian J Jagust; John Kornak; Katherine P Rankin; Lea T Grinberg; Harry V Vinters; Mario F Mendez; Dennis W Dickson; William W Seeley; Marilu Gorno-Tempini; Joel Kramer; Bruce L Miller; Adam L Boxer; Gil D Rabinovici
Journal:  Alzheimers Res Ther       Date:  2015-03-02       Impact factor: 6.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.